Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 4/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7464745 | 0.82 | CTSK (0.71) | CTSKPSMB5CTSSCTSBCNR2 | |
| SCHEMBL10784901 | 0.76 | CTSK (0.56) | CTSKPSMB5CTSSCTSBCNR2 | |
| SCHEMBL7468216 | 0.73 | CTSK (0.53) | CTSKPSMB5CTSSCTSBCNR2 | |
| SCHEMBL7248005 | 0.73 | CTSK (0.59) | CTSKPSMB5CTSSSCN9AUSP30 | |
| SCHEMBL7563718 | 0.71 | CTSK (0.69) | CTSKCTSSCTSBCNR2CTSL | |
| SCHEMBL7560380 | 0.71 | CTSK (0.49) | CTSKPSMB5CTSSCTSBCNR2 | |
| SCHEMBL7463889 | 0.68 | CTSL (0.49) | CTSKPSMB5CTSSCTSBCNR2 | |
| SCHEMBL7530060 | 0.68 | CTSK (0.69) | CTSKCTSSCTSBCTSLKMT2A | |
| SCHEMBL7160519 | 0.67 | CTSK (0.63) | CTSKCTSSCTSBCTSL | |
| SCHEMBL6923555 | 0.67 | CTSK (1.00) | CTSKCTSSCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSK 22/4885PSMB5 487/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.